cyclic-gmp and Polycystic-Kidney-Diseases

cyclic-gmp has been researched along with Polycystic-Kidney-Diseases* in 3 studies

Other Studies

3 other study(ies) available for cyclic-gmp and Polycystic-Kidney-Diseases

ArticleYear
Cyclic nucleotide signaling in polycystic kidney disease.
    Kidney international, 2010, Volume: 77, Issue:2

    Increased levels of 3'-5'-cyclic adenosine monophosphate (cAMP) stimulate cell proliferation and fluid secretion in polycystic kidney disease. Levels of this molecule are more sensitive to inhibition of phosphodiesterases (PDEs), whose activity far exceeds the rate of cAMP synthesis by adenylyl cyclase. Several PDEs exist, and here we measured the activity and expression of PDE families, their isoforms, and the expression of downstream effectors of cAMP signaling in the kidneys of rodents with polycystic kidney disease. We found a higher overall PDE activity in kidneys from mice as compared with rats, as well as a higher contribution of PDE1, relative to PDE4 and PDE3, to total PDE activity of kidney lysates and lower PDE1, PDE3, and PDE4 activities in the kidneys of cystic as compared with wild-type mice. There were reduced amounts of several PDE1, PDE3, and PDE4 proteins, possibly due to increased protein degradation despite an upregulation of their mRNA. Increased levels of cGMP were found in the kidneys of cystic animals, suggesting in vivo downregulation of PDE1 activity. We found an additive stimulatory effect of cAMP and cGMP on cystogenesis in vitro. Cyclic AMP-dependent protein kinase subunits Ialpha and IIbeta, PKare, the transcription factor CREB-1 mRNA, and CREM, ATF-1, and ICER proteins were upregulated in the kidneys of cystic as compared with wild-type animals. Our study suggests that alterations in cyclic nucleotide catabolism may render cystic epithelium particularly susceptible to factors acting on Gs-coupled receptors. This may account, in part, for increased cyclic nucleotide signaling in polycystic kidney disease and contribute substantially to disease progression.

    Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antidiuretic Hormone Receptor Antagonists; Blotting, Western; Cell Line; Collagen; Cyclic AMP Response Element Modulator; Cyclic GMP; Isoenzymes; Mice; Polycystic Kidney Diseases; Polymerase Chain Reaction; Rats; RNA, Messenger; Signal Transduction; Up-Regulation

2010
Thiophenecarboxylate suppressor of cyclic nucleotides discovered in a small-molecule screen blocks toxin-induced intestinal fluid secretion.
    Molecular pharmacology, 2009, Volume: 75, Issue:1

    We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC(50) of <5 microM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl(-) current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors.

    Topics: Animals; Cell Line; Cells, Cultured; CHO Cells; Cholera Toxin; Cricetinae; Cricetulus; Cyclic AMP; Cyclic GMP; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Dogs; Inorganic Chemicals; Intestinal Secretions; Kidney; Mice; Mice, Inbred Strains; Molecular Structure; Nucleotides, Cyclic; Polycystic Kidney Diseases; Rats; Rats, Inbred F344; Stereoisomerism; Structure-Activity Relationship; Thyroid Gland; Transfection

2009
A study on regulating factors of plasma refilling during hemodialysis.
    Nephron, 1996, Volume: 74, Issue:1

    Hypotension is frequently encountered during hemodialysis (HD). One of the main factors of the HD-induced hypotension is acute reduction of circulating plasma volume by water removal, which is induced by the poor plasma refilling from the extravascular space into vessels. The determinants of plasma refilling, however, have not been clearly identified. Recently, we devised a mathematical model of water transport in HD patients, which can estimate the plasma-refilling coefficient (Kr) during HD. In the present study, we evaluated the factors determining plasma refilling by using this model. In 13 patients undergoing regular HD, the changes of Kr during HD were calculated from the model. Levels of ANP, cGMP, cAMP, endothelin, angiotensin II and vasopressin were measured before and after HD. Kr fell from 750.4 +/- 558.0 to 112.8 +/- 81.9 ml/mm Hg/h during HD. The rate of water removal during HD showed no significant correlation with the changes of Kr. Among the hormones and nucleotides measured here, plasma ANP level and cGMP were significantly correlated with Kr (r = 0.78, p < 001 and r = 0.62, p < 0.01, respectively). Our findings suggest that severe reduction in the level of serum ANP during HD, which is induced by water removal, plays some role in HD-induced hypotension through the attenuation of plasma refilling in HD patients.

    Topics: Adult; Aged; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Blood Vessels; Cyclic AMP; Cyclic GMP; Endothelins; Female; Fluid Shifts; Glomerulonephritis; Hematocrit; Hemodynamics; Humans; Male; Middle Aged; Nephrosclerosis; Plasma; Polycystic Kidney Diseases; Renal Dialysis; Vasopressins; Water

1996